A n improved method of measuring changing glomerular filtration rate (GFR) during acute kidney injury (AKI) would be of immense benefit. We need a method of properly evaluating biomarkers, which to date have been compared with flawed serum creatinine (SCr) measurements and found to be wanting. Accurate assessment of AKI is required to facilitate dosing of renally excreted drugs (1) , to identify progression to renal replacement therapy (RRT) (2) and to predict those patients most vulnerable to the development of chronic kidney disease (CKD). In research, an improved measurement of GFR would help elucidate the temporal relationship between changing GFR during AKI and pathophysiologic consequences.
AKI is defined by increased SCr concentration or reduced urine output (3) . Both parameters have limitations in critically ill patients (4) .
Theoretically, exogenous filtration markers have advantages over endogenous markers when measuring GFR during AKI. Measurements are not influenced by diet, metabolic processes, or body habitus and are independent of the time of the insult causing AKI. Single bolus injection (SBI) of Iohexol has been used to measure GFR in critically ill patients (5, 6) , but SBI has methodologic limitations. Stable GFR is needed for accurate interpretation-the elimination constant changes during AKI. Multiple administrations are required to measure changing GFR, leading to larger administered volumes than with continuous infusions, increasing potential for toxicity. Prolonged washout periods are needed for complete elimination before the next dose is administered. Changes in volume of distribution (Vd) or nonrenal clearance (Cl NON-RENAL ) in critically ill patients mean that a prolonged time is required before plasma clearance (Cl P ) is equivalent to renal clearance (Cl R ). Continuous infusions of Inulin (7) and EDTA (8) have been used to measure GFR in critically ill patients but only for less than 4 hours. This is too short for understanding the impact of changes in GFR and development of AKI.
We have previously developed a continuous infusion of low-dose Iohexol (CILDI) as a measure of GFR in stable subjects over a range of GFR (28-128 mL/min/1.73 m 2 ) (9). Accuracy of CILDI was confirmed with the SBI method. Mean intraindividual variation in Cl P was less than 10.3% ± 7.4% and variation in Cl R was less than 6.9% ± 4.7% (9) .
We hypothesize that variations in excess of these limits suggest that AKI is present and that CILDI can accurately and precisely measure changing GFR during AKI. The aim of this study is to explore CILDI as a measure of changing GFR in patients with different risks of developing AKI.
METHODS
Detailed methods are outlined in the supplementary online material (Supplemental Digital Content 1, http://links.lww. com/CCM/D37).
Study Registration and Ethical Approval
The UK Clinical Research Network (http://public.ukcrn. org.uk/) adopted the study (reference: 13391). Ethical approval was obtained from Queen's Square research ethics committee (reference: 12/LO/1179). The Declaration of Helsinki (2008) (10) was adhered to throughout.
Patients
The study took place in an adult general ICU. Three patient groups were selected: 1) nephrectomy: patients due an elective nephrectomy and thus a predictable reduction in GFR of approximately 50% (defined onset of injury; predictable outcome). 2) Surgery: patients due elective major vascular surgery. These patients have a high risk of postoperative AKI (11) (defined onset of injury; unpredictable outcome). 3) AKI: emergency patients admitted to ICU meeting Kidney Disease: Improved Global Outcomes (KDIGO) AKI criteria (3) (unpredictable onset of injury; unpredictable outcome).
Inclusions
• Patients over 18 years due an elective nephrectomy or major vascular surgery admitted to ICU postoperatively or • Patients meeting KDIGO-AKI criteria (urine output or SCr) in ICU (3).
Exclusions
See supplementary online material (Supplemental Digital Content 1, http://links.lww.com/CCM/D37).
Iohexol Administration and Sampling
Iohexol was administered via a central venous catheter. A loading dose was administered over 2 minutes (9) and followed by a continuous infusion of Iohexol (Omnipaque 300; GE Healthcare, Princeton, NJ) (12) at 0.5 mL/hr (343.5 mg/hr) for up to 80 hours (13) . Plasma samples (0.5 mL) were taken for Cl P at 30 minutes, 1 hour, 2 hours, and 4 hours on day 0, and at 08:00 hours, 10:00 hours, 18:00 hours, and 20:00 hours on days 1-3 from an arterial catheter. Urine samples were taken for Cl R between plasma samples on day 0 and between subsequent morning plasma samples and evening plasma samples. Time zero was considered to be the time of commencing the infusion. Infusions were commenced within 1 hour of surgery in the surgery and nephrectomy groups.
Laboratory Procedures and GFR Calculation
Plasma and urine Iohexol concentration were measured by high-performance liquid chromatography/electrospray tandem mass spectrometry (LC-MSMS) (Online supplementary material, Supplemental Digital Content 1, http://links. lww.com/CCM/D37). Baseline estimated GFR (eGFR) was obtained from admission eGFR (14) for elective patients or from hospital notes if within the last 6 months. The following formulae were used: Cl P (mL/min) = [Iohexol infusion rate (μmol/min)]/ [plasma Iohexol concentration (μmol/mL)], adjusting for body surface area (BSA) (15) .
Cl R (mL/min) = [U × V]/P, where U = urine Iohexol concentration (μmol/L), V = volume of urine (mL) per unit time (min), and P = mid-time point plasma Iohexol concentration (μmol/L), adjusting for BSA (15) . Agreement With KDIGO and Outcomes Iohexol GFR measurements and KDIGO-AKI criteria were observed and classified according to whether subjects met KDIGO and CILDI criteria for AKI: KDIGO-positive (Kpos), KDIGO-negative (Kneg), CILDI-positive (Cpos), CILDI-negative (Cneg). Length of stay in ICU and hospital, development of CKD within 1 year, need for RRT, and death were recorded. CILDI defined AKI as GFR loss greater than 10.3% (9) .
Statistical Methods
The data have been graphically explored and summarized according to their nature. Cross-sectional (one measurement per individual) have been summarized through means, medians, sd, and interquartile ranges while categorical data have been summarized as proportions. Parametric or nonparametric tests have been tailored to variables' nature. For hierarchical longitudinal data (multiple measurements per individual through time), nonlinear mixed models have been employed. Details are given in the supplementary material (Supplemental Digital Content 1, http://links.lww.com/CCM/D37).
The analysis is not aiming at inferring differences between clinical groups. They differ by their default clinical definition. Rather, the statistical techniques are used exploratory, with the view of opening up novel methods or indicators that can contribute to the AKI definition.
RESULTS

Screening, Enrollment, Demographics
Eleven subjects were enrolled into the nephrectomy and surgery groups, and 13 into the AKI group ( Table 1) . One patient in the nephrectomy group was excluded from analysis due to difficult venous access.
GFR
Cl P and Cl R were calculated for each measurement taken on days 1-3. Measurements at 24 hours are shown in Table 2 .
Agreement Between Cl P and Cl R Agreement (16) between Cl R and Cl P improved with increasing duration of the infusion (Fig. 1) .
Clinical and Laboratory Accuracy
Measured loss in GFR (Cl R ) at 24 hours in the nephrectomy group was 50.8% ± 17.6% as hypothesized from the loss of one kidney (Table 2 ; Supplementary Fig. 3 , Supplement Digital Content 8, http://links.lww.com/CCM/D44; legend, Supplemental Digital Content 1, http://links.lww.com/CCM/D37). For the laboratory analysis of samples, coefficient of variation (CV) for measuring Iohexol was 2.4% (n = 180 samples).
AKI Misdiagnosis and Outcomes
Iohexol Cl R and Cl P are compared with 1-and 4-hour CrCl at 14 hours ( Table 3) . KDIGO-AKI criteria would have missed AKI in nine patients (nephrectomy group: 5, surgery group: 4); three subjects meeting KDIGO-AKI criteria did not have AKI when measured by CILDI ( Table 4) . Patients who were Kneg/ Cpos had higher proportion of CKD at 1 year than Kpos/Cneg.
DISCUSSION
Summary of Results
We have used CILDI to measure GFR during AKI over the range encountered in critically ill patients despite potential fluctuations in Vd and third space accumulation of fluids that may occur.
Demographics are shown in Table 1 . The Surgery group had a reduced baseline eGFR reflecting the increased comorbidities in this group. Acute Physiology and Chronic Health Evaluation-II score was highest in the AKI group and lowest in nephrectomy group. This was an expected observation related to the varying clinical presentations and complexity of disease.
There was no difference between Cl P and Cl R in all groups when GFR was measured at 24 hours (Table 2) . Agreement between Cl R and Cl P improved at later stages of the infusion, suggesting a longer period is required for equilibration either caused by a change in Cl NON-RENAL in critical illness or due to increased Vd. Bland-Altman analysis (16) showed agreement between Cl P and Cl R improves with longer duration of infusion, with less than 1% bias and acceptable limits of agreement in later stages (Fig. 1) .
All nephrectomy patients underwent surgery for unilateral renal cell carcinomas and 10 had baseline eGFR greater than 50 mL/min/1.73 m 2 . One patient had an eGFR 39.7 mL/ min/1.73 m 2 , and we measured differential renal function. GFR was equal in both kidneys. The remaining patients had uncomplicated disease, and we therefore expected a 50% reduction in GFR following nephrectomy. The observed 50.8% reduction at 24 hours ( Fig. 1; Supplementary Fig. 3 , Supplement Digital Content 8, http://links.lww.com/CCM/D44; legend, Supplemental Digital Content 1, http://links.lww.com/CCM/ D37) suggests that CILDI may provide an accurate measure of GFR.
Brenner's theory suggests an immediate increase in single nephron GFR (SNGFR) following nephrectomy (17) . Increases in blood flow and SNGFR have been observed in animal studies (18) . Data are inconsistent in human studies: some confirm increased single kidney GFR several days postnephrectomy (19) , others suggest that it is delayed for up to 36 months (20) . Increased blood flow to the remaining kidney has been reported postnephrectomy (19) , but there is a paucity of studies investigating GFR in the immediate postoperative period. We observed increasing GFR after 24 hours following nephrectomy although numbers were too small for complete statistical analysis.
The 10.3% difference in Cl P and 6.7% difference in Cl R to define AKI is a significant contrast to KDIGO-AKI criteria where a rise in SCr greater than 50% is required (3), resulting in a different proportion of patients meeting criteria for AKI. This is not unusual when different methods of defining AKI are compared (21) . Using CILDI criteria, KDIGO-AKI criteria miss AKI in five patients in the nephrectomy group, four in the surgery group, and erroneously attribute AKI to two patients in the AKI group. All patients who were Kpos/Cneg (Table 4) had oliguria and raised SCr at 24 hours. Creatinine kinetics studies estimate a GFR reduction of 50% must occur to increase SCr by 100% (22) (i.e., stage 2 KDIGO-AKI (3)). To further evaluate our method, we looked at the rate of AKI if defined by a 10.3% reduction in GFR and also if defined by a 50% reduction in GFR measured by CILDI to define AKI. In both situations, CILDI would detect more AKI than stage 1 KDIGO criteria (Table 4) . We chose not to enroll a "control" group of ICU patients without KDIGO criteria AKI because we would miss false-negatives of KDIGO. Using KDIGO-negative, AKI patients to define the limits of precision for CILDI-AKI would inevitably show no difference to KDIGO and would thus render our method susceptible to the flaws of using creatininebased definitions as comparators. SCr is a poor marker of GFR in critically ill patients and may not increase as predicted by creatinine kinetic modeling (22) . Its formation may be reduced and its secretion increased in critical illness (23) and sepsis (24) and fluid resuscitation may dilute SCr. This combination of factors and the ensuing dynamic changes may result in AKI being underdiagnosed or even overdiagnosed. Other endogenous markers have not yet proven to be sensitive and specific enough in a heterogeneous group of patients or when onset of the insult causing AKI is unknown. However, they have only been tested against SCr.
Studies have suggested that 4-hour CrCl is a useful surrogate for changing GFR during AKI (25), and we have used it previously to evaluate the use of calculated GFR in AKI (26) . Our data suggest that it lacks sufficient precision to be useful clinically (Table 3) . One-hour CrCl may be a better choice than 4-hour CrCl when assessed against Cl R of Iohexol.
Our data are too few to investigate outcomes fully, but eight of nine patients who were Kneg/Cpos developed CKD, whereas none of the three patients who were Kpos/Cneg developed CKD within 1 year.
Exogenous filtration markers have previously been used in ICU. Erley et al (5) used the SBI technique, but this method cannot be used for monitoring changing GFR during AKI. Salmon-Gandonnière et al (6) observed a close correlation between a single Cl P after SBI, measured over 12 hours, and mean Cl R estimated on four separate occasions over the subsequent 24 hours. These findings are inconsistent with our data: we have demonstrated that a prolonged duration of infusion is required before a close agreement between Cl P and Cl R is observed (Fig. 1) . Caution needs to be applied when interpreting GFR measurements in AKI that are solely based upon Cl P or SBI methods.
Inulin (7) and EDTA (8) infusions have been used for 4 hours (7); however, inulin is in short supply with increased manufacturing costs (27) and EDTA has risks associated with radiation exposure. Neither have been tested with prolonged infusions.
Iohexol has many properties of an "ideal marker" of filtration (28): it undergoes minimal protein binding, almost all is filtered at the glomerulus, it undergoes no renal tubular reabsorption or secretion, it diffuses rapidly into extracellular spaces, and it has an excellent safety profile (29) . Highly reproducible laboratory results with low inter-and intrapatient CV are observed when Iohexol is measured by LC-MSMS (30) . LC-MSMS measurements of Iohexol concentration are more accurate than routine laboratory SCr measurements (30) . Iohexol is widely available and is 5-10% the cost of Inulin and 15% the cost of measuring GFR with Inulin.
Limitations
The CKD-Epidemiology (EPI) equation was used to estimate baseline GFR, rather than measured GFR. Measuring GFR in elective patients was not possible due to the logistics of being a specialist centre and the distances patients have to travel. However, CKD-EPI is an established method in stable patients (14) . Critical Care Medicine www.ccmjournal.org e195
Wider differences between Cl P and Cl R were observed when measured at lower GFR. This may suggest an increased role for Cl NON-RENAL or that these were sicker patients with greater changes in Vd. Agreement between Cl R and Cl P improved at later stages of infusion, suggesting a longer time is needed for redistribution between extracellular spaces in critically unwell patients than in our previously studied patients with stable GFR (9) . Despite this, a good agreement between Cl R and Cl P was observed, particularly in later stages of the study.
Continuous infusions are too cumbersome for daily clinical practice but could be a useful research tool. CILDI offers a method of measuring changing GFR in AKI in clinical trials (e.g., comparing biomarkers with accurately measured GFR, measuring the effects of AKI on pathophysiologic processes (31)).
Older radiocontrast agents have been associated with AKI (32) although this relationship may not be causative (33) (34) (35) (36) (37) . AKI occurring after contrast administration is likely to be multifactorial and may be more attributable to the underlying illness than radiocontrast. A threshold ratio of radiocontrast volume to weight and baseline eGFR has been suggested before contrast-associated AKI develops (38) . By keeping the infused volume low, this risk is minimized. In our method, infusion for more than 6 days would be required before this threshold was exceeded in an anuric 40 kg patient. Alternatively, SBI methods (5, 6) would require repeated administration of larger volumes of Iohexol and the threshold for toxicity would be exceeded sooner. The debate surrounding contrast-associated AKI remains unresolved; a delayed nephrogram may be considered in patients with known low, or rapidly declining, GFR. 
Next Stages
The method was developed primarily for research purposes, but it does provide opportunity to describe AKI more accurately and to assess more clinically applicable methods. This, in turn, will allow clinicians to understand AKI in more detail. Biomarkers may be assessed more precisely and a definition of AKI better formulated: some biomarkers may be better than we realize. Improving AKI definitions will allow treatments to be tested accurately and could provide guidance on when to commence RRT. Early initiation of RRT may have survival advantages (39) . In research, CILDI could improve investigation of biomarkers, of pathophysiology (31) , and mechanisms of AKI. Although CILDI defines AKI as GFR reduction of greater than 10.3%, it is unclear whether symptoms manifest at this level of change, whether the rate of reduction in GFR is responsible for associated effects, or if a critical reduced GFR must be reached. Further research in this area is required; however, CILDI allows tracking of AKI and can help answer these questions. Furthermore, greater numbers are needed to determine whether small changes in GFR measured by CILDI have measurable differences in outcomes when compared with SCr.
